A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an anti-Toll Like Receptor 4 Monoclonal Antibody in Patients with Rheumatoid Arthritis

Trial Profile

A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an anti-Toll Like Receptor 4 Monoclonal Antibody in Patients with Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs NI 0101 (Primary)
  • Indications Rheumatoid nodule
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors NovImmune SA
  • Most Recent Events

    • 17 May 2017 Status changed from planning to recruiting.
    • 15 Dec 2016 New trial record
    • 05 Dec 2016 According to a Novimmune media release, under the terms of the agreement, Genentech receives an exclusive option to license all rights to develop and commercialize NI-0101, pending the results of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top